In Week of Mar 28, 2026, Sai Life Sciences Ltd (Pharma - Formulators) is outperforming Nifty 500 with +21.6% relative strength. Fundamentals: Average. On a 7-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Seven new molecules added to late-phase/commercial pipeline supporting 31% CDMO revenue growth
Impact: +₹150 Cr revenue
“Added seven molecules to late phase and commercial pipeline, enhancing business resilience”
What: New manufacturing capacity coming online to support revenue growth
Impact: +₹300 Cr revenue
“On track with capital expenditure program, with several expansions scheduled for completion in the near future”
Earnings deceleration risks from management commentary
Trigger: If customers reduce inventory levels
Impact: -200 bps margin impact
Management view: Currently no specific visibility of such events
Monitor: Quarterly revenue growth rate
Trigger: Demand shift for top product
Impact: -150 bps margin impact
Management view: Not directly addressed in call
Monitor: Top customer/product concentration
Key quotes from recent conference calls
“The expansion is due to business and product mix, as well as operating leverage from employee costs. We expect to sustain margins in the 28% to 30% range. — Siva Chittor”
“Capital expenditure totaled ₹405 crore as of the quarter-end, on track toward the FY26 plan of ₹700 crore, focusing on manufacturing and process development infrastructure. — Company statement”
“Growth was broad-based across the portfolio with the CDMO business contributing approximately 65% of the revenues and the CRO business contributing the remaining 35%. — Company statement”
“We expect to sustain this margin range of 28 to 30% to enable us maximize growth while managing growth related challenges and optimizing margin. — Company statement”
Forward-looking targets from management for Next 2-4 quarters
OPM Guidance
28%
Capex Plan
₹700 Cr
Key Milestones
• Sustain 28-30% EBITDA margins
• Complete ₹700 cr capex program
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +26% | +25% | Stable |
| PAT (Net Profit) | +85% | +80% | Stable |
| OPM | 34.0% | +700 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Sai Life Sciences Ltd's latest quarterly results (Dec 2025) show
Sai Life Sciences Ltd's profit is growing with an stable trend.
Sai Life Sciences Ltd's revenue growth trend is stable.
Sai Life Sciences Ltd's operating margin is volatile.
Sai Life Sciences Ltd's long-term compounding rates
Sai Life Sciences Ltd's earnings growth is stable with mixed signals on a sequential basis.
Sai Life Sciences Ltd's trailing twelve month (TTM) performance
Sai Life Sciences Ltd appears significantly overvalued based on our fair value analysis.
Sai Life Sciences Ltd's current PE ratio is 61.6x.
Sai Life Sciences Ltd's current PE is 61.6x.
Sai Life Sciences Ltd's price-to-book ratio is 9.2x.
Sai Life Sciences Ltd is rated Average with a fundamental score of 43.27/100. This score is calculated from objective financial metrics
Sai Life Sciences Ltd has a debt-to-equity ratio of N/A.
Sai Life Sciences Ltd's return ratios over recent years
Sai Life Sciences Ltd's operating cash flow is positive (FY2025).
Sai Life Sciences Ltd currently does not pay a significant dividend (yield 0.00%).
Sai Life Sciences Ltd's shareholding pattern (Dec 2025)
Sai Life Sciences Ltd's promoter holding has decreased recently.
Sai Life Sciences Ltd has been outperforming Nifty 500 for 7 consecutive weeks, indicating building momentum.
Sai Life Sciences Ltd is an established outperformer with 7 weeks of consecutive Nifty 500 outperformance.
Sai Life Sciences Ltd has 2 key growth catalysts identified from recent earnings analysis
Sai Life Sciences Ltd has 2 key risks worth monitoring
In Q3 FY26, Sai Life Sciences Ltd's management highlighted
Sai Life Sciences Ltd's management has provided the following forward guidance for Next 2-4 quarters
Based on quantitative research signals, here is why Sai Life Sciences Ltd may be worth studying
Sai Life Sciences Ltd investment thesis summary:
Sai Life Sciences Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
